KR880004802A - 서방성(徐放性) 입자 제제 및 이의 제조방법 - Google Patents

서방성(徐放性) 입자 제제 및 이의 제조방법 Download PDF

Info

Publication number
KR880004802A
KR880004802A KR870011169A KR870011169A KR880004802A KR 880004802 A KR880004802 A KR 880004802A KR 870011169 A KR870011169 A KR 870011169A KR 870011169 A KR870011169 A KR 870011169A KR 880004802 A KR880004802 A KR 880004802A
Authority
KR
South Korea
Prior art keywords
molecular weight
preparation
compound
sustained
active agent
Prior art date
Application number
KR870011169A
Other languages
English (en)
Other versions
KR930007247B1 (ko
Inventor
미노루 마치다
마시유기 아라가와
Original Assignee
원본미기재
쭈가이세이야꾸 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 쭈가이세이야꾸 가부시기가이샤 filed Critical 원본미기재
Publication of KR880004802A publication Critical patent/KR880004802A/ko
Application granted granted Critical
Publication of KR930007247B1 publication Critical patent/KR930007247B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

서방성(徐放性) 입자 제제 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 및 제2도는 본 발명의 실시예 1 및 2에서 제조된 G-CSF 및 조절제로서 G-GSF의 수용액을 함유한 서방성 입자제제를 피하내 및 근육내 주입후에 혈액샘플에서 말초호중구 농도의 변화를 나타낸 그래프이다.

Claims (5)

  1. 생체내에서 분해될 수 있고, 생체조직에 적합한 중합체 화합물, 약리학적 활성제, 및 당원류의 천연고분자량 화합물 또는 이것의 유도체를 함유하는 것을 특징으로 하는 서방성 입자제제.
  2. 제1항에 있어서, 상기 중합체 화합물은, 폴리유산(polyacticacid), 폴리글리코올산, 폴리히드로부티릭산 또는 이것의 공중합체인 것을 특징으로 하는 서방성 입자제제.
  3. 제1항에 있어서, 상기 당원류의 천연고분자량 화합물 또는 이것의 유도체는 키틴 및 이것의 유도체, 키로산 및 이것의 유도체, 히알우론산 및 이것의 염, 약 10,000 내지 약 150,000의 분자량을 가지는 덱스트란, 펙틴, 약 2,500 내지 약 150,000의 분자량을 가지는 덱스트린, 및 콘드로이틴 설페이트 및 이것의 염으로 구성된 그룹에서 선택되는 것을 특징으로 하는 서방성 입자체제.
  4. 제1항에 있어서, 상기 약리학적 활성제는 유기 화합물이 아니며, 물에 불용이거나 물에 잘녹지 않는 단백질 또는 팹티드인 것을 특징으로 하는 서방성 입자제제.
  5. (1) 생체내에서 분해될 수 있고 생체조직에 적합한 중합체화합물을 유기용매에 용해시키고; (2) 약리학적 활성제를 상기(1)에서 제조한 용액과 혼합시키고, (3) 당원류의 천연고분자량 화합물의 수용액을 상기(2)에서 제조한 혼합물과 혼합시키고, 이혼합물을 교반시켜서 생리학적 활성제를 함유한 미세입자제제를 제조하고; 및 (4)여기서 만들어진 미세입자를 혼합물로부터 분리하는 단계를 포함하는 것을 특징으로 하는 것을 특징으로 하는 서방성 입자제제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870011169A 1986-10-07 1987-10-06 서방성(徐放性) 미립제제 KR930007247B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP61-237027 1986-10-07
JP61237027A JPH0725689B2 (ja) 1986-10-07 1986-10-07 顆粒球コロニ−刺激因子を含有する徐放性製剤
JP237027 1986-10-07

Publications (2)

Publication Number Publication Date
KR880004802A true KR880004802A (ko) 1988-06-27
KR930007247B1 KR930007247B1 (ko) 1993-08-04

Family

ID=17009307

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870011169A KR930007247B1 (ko) 1986-10-07 1987-10-06 서방성(徐放性) 미립제제

Country Status (10)

Country Link
US (1) US4853226A (ko)
EP (1) EP0263490B1 (ko)
JP (1) JPH0725689B2 (ko)
KR (1) KR930007247B1 (ko)
AT (1) ATE116540T1 (ko)
AU (1) AU608250B2 (ko)
CA (1) CA1315200C (ko)
DE (1) DE3750943T2 (ko)
ES (1) ES2068810T3 (ko)
GR (1) GR3015485T3 (ko)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
JPH02212436A (ja) * 1989-02-14 1990-08-23 Japan Atom Energy Res Inst 徐放性基剤
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6136793A (en) * 1992-02-20 2000-10-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition of microspheres with several delayed release nuclei and its preparation process.
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3390477B2 (ja) 1993-01-25 2003-03-24 生化学工業株式会社 薬剤組成物及びその製造法
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5478355A (en) * 1993-03-18 1995-12-26 United States Surgical Corporation Method for improving the in vivo strength retention of a bioabsorbable implantable medical device and resulting medical device
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
EP0862419B2 (en) 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
IL136230A0 (en) * 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
EP0978285B1 (en) 1998-08-07 2005-11-23 F. Hoffmann-La Roche Ag Stable pharmaceutical composition of hedgehog proteins and use thereof.
PT1146861E (pt) * 1999-02-03 2005-10-31 Powderject Res Ltd Formulacoes de particulas de hidrogel
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1867348B1 (en) * 1999-03-25 2012-05-16 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
WO2002094321A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20050191361A1 (en) * 2001-08-03 2005-09-01 Powederject Research Ltd. Hydrogel particle formation
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
US20040226620A1 (en) 2002-09-26 2004-11-18 Daniel Therriault Microcapillary networks
EP1563840A1 (en) * 2002-10-22 2005-08-17 Japan Science and Technology Agency Dengue virus infection inhibitor
US7053125B2 (en) 2002-11-14 2006-05-30 The Board Of Trustees Of The University Of Illinois Controlled dispersion of colloidal suspension by comb polymers
DK1638615T3 (en) 2003-05-08 2015-01-12 Tepha Inc MEDICAL POLYHYDROXYALKANOATE TEXTILES AND FIBERS
US7141617B2 (en) 2003-06-17 2006-11-28 The Board Of Trustees Of The University Of Illinois Directed assembly of three-dimensional structures with micron-scale features
CA2531833C (en) * 2003-07-08 2009-10-20 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
EP1663017A1 (en) * 2003-08-22 2006-06-07 Tepha, Inc. Polyhydroxyalkanoate nerve regeneration devices
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
FI116625B (fi) 2004-01-28 2006-01-13 Macrocrystal Oy Menetelmä proteiinien kiteyttämiseksi hiilihydraattirunkoisilla polymeereillä
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
ATE473021T1 (de) * 2004-08-03 2010-07-15 Tepha Inc Nichtkräuselnde polyhydroxyalkanoatnähte
DE602006016915D1 (de) * 2005-01-28 2010-10-28 Tepha Inc Embolisierung unter verwendung von poly-4-hydroxybutyrat-partikeln
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
CN101522164B (zh) * 2006-09-13 2014-03-26 提升肤质产品公司 用于治疗皮肤的化妆品组合物及其方法
US7943683B2 (en) * 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
US7956102B2 (en) 2007-04-09 2011-06-07 The Board Of Trustees Of The University Of Illinois Sol-gel inks
US7922939B2 (en) 2008-10-03 2011-04-12 The Board Of Trustees Of The University Of Illinois Metal nanoparticle inks
US8187500B2 (en) 2008-10-17 2012-05-29 The Board Of Trustees Of The University Of Illinois Biphasic inks
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
CN102481332A (zh) 2009-06-14 2012-05-30 拜欧肯疗法有限公司 用于提高血小板水平的肽疗法
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
ES2807178T3 (es) 2014-08-15 2021-02-22 Tepha Inc Suturas de autorretención de poli-4-hidroxibutirato y copolímeros del mismo
CA2969429C (en) 2014-12-11 2020-10-27 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
CN115970051B (zh) * 2023-02-09 2023-08-29 辽宁天贺生物科技研究院有限公司 可降解组织工程填充材料及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
JPS5933214A (ja) * 1982-08-19 1984-02-23 Mitsui Toatsu Chem Inc 微小球に製剤された制ガン剤の製造方法
CH660488A5 (en) * 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6163613A (ja) * 1984-09-04 1986-04-01 Mitsui Toatsu Chem Inc 顆粒状に調整された徐放性製剤
JPS6165816A (ja) * 1984-09-10 1986-04-04 Mitsui Toatsu Chem Inc 顆粒状の徐放性製剤
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
WO1986004605A1 (en) * 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
JPS61277612A (ja) * 1985-05-31 1986-12-08 Kiyoshi Morikawa 接種用徐放性組成物
ATE67517T1 (de) * 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤

Also Published As

Publication number Publication date
KR930007247B1 (ko) 1993-08-04
ATE116540T1 (de) 1995-01-15
AU608250B2 (en) 1991-03-28
EP0263490B1 (en) 1995-01-04
EP0263490A2 (en) 1988-04-13
AU7940487A (en) 1988-04-14
EP0263490A3 (en) 1990-05-16
CA1315200C (en) 1993-03-30
JPS6391325A (ja) 1988-04-22
JPH0725689B2 (ja) 1995-03-22
GR3015485T3 (en) 1995-06-30
US4853226A (en) 1989-08-01
DE3750943D1 (de) 1995-02-16
ES2068810T3 (es) 1995-05-01
DE3750943T2 (de) 1995-05-11

Similar Documents

Publication Publication Date Title
KR880004802A (ko) 서방성(徐放性) 입자 제제 및 이의 제조방법
CA2140053C (en) Collagen-based injectable drug delivery system and its use
DE69925156T2 (de) Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen
US4492684A (en) Slow release injectable insulin composition
Jameela et al. Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle
US4675189A (en) Microencapsulation of water soluble active polypeptides
JP2537602B2 (ja) 安定性タンパク質及びタンパク質の安定化法
JP3094074B2 (ja) 多糖ゲル組成物
HU228462B1 (en) Implant for subcutaneous or intradermal injection
HU186904B (en) Process for producing retarde pharmaceutical compositions
CA2609891A1 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
KR860006985A (ko) 비경구 투여를 위한 수분산성 및 수용성 중합체 조성물
JP4636883B2 (ja) 薬物徐放担体
EP0540582A1 (en) GROWTH HORMONE CRYSTALS AND PROCESS FOR PRODUCING THE SAME.
CN1739795A (zh) 甲状旁腺激素缓释微球的制备方法
AU708084B2 (en) Peptide and a method of obtaining it
DE3881615T2 (de) Wasserunloesliche cytokine.
JPWO2004050712A1 (ja) 薬物徐放担体
EP4063433A1 (en) Hydrogel of mercapto-modified macromolecular compound, and preparation method therefor and use thereof
WO2008033058A2 (fr) Procédé permettant de produire une préparation d'insuline pour administration orale
CN113384749A (zh) 用于促进血运长效开放的多功能水凝胶及其制备方法
JPH0616702A (ja) 修飾ヒアルロン酸、その製造方法及びそれを用いた徐放化製剤
JP2817063B2 (ja) 徐放性血管拡張剤
CN109846855A (zh) 一种生物素化白蛋白纳米粒及其制备方法与应用
JPH0597661A (ja) 薬物徐放剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060719

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee